Amgen, already on PCSK9 offense, slaps Sanofi, Regeneron with Dupixent patent suit tracy Thu, 04/20/2017 – 09:09 More: Amgen, already on PCSK9 offense, slaps Sanofi, Regeneron with Dupixent patent suit Source: fierce
read moreAbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer. More: AbbVie’s PARP inhibitor fails in PhIII trials Source: News
read moreNovartis has announced the publication of data showing high response rates in patients with the rare blood disorder severe aplastic anaemia (SAA) taking its medicine eltrombopag, supporting its first-line use for the condition. More: Data back first-line use of Novartis’
read moreGW Pharma’s Epidiolex has impressed again in a late-stage trial involving patients with the rare form of epilepsy Lennox-Gastaut Syndrome (LGS), significantly reducing the number of drop seizures experienced. More: GW’s Epidiolex on track for LGS filing mid-year Source: News
read moreIpsen says discussions with the National Institute for Health and Care Excellence are ongoing following a second rejection of Cabometyx for advanced renal cell carcinoma (RCC). More: Ipsen in talks with NICE over Cabometyx rejection Source: News
read moreRoche More: Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Source: MDlinx
read more© 1994 - 2026 B.M. Pharmaceuticals